[1]Steinbrook R. The potential of human papillomavirus vaccines [J]. N Engl J Med, 2006, 354(11):1109-1112.
[2]Stanley M. HPV vaccines [J]. Best Pract Res Clin Obstet Gynaecol, 2006, 20(2):279-293.
[3]Roden R, Wu TC. How will HPV vaccines affect cervical cancer[J]？ Nat Rev Cancer, 2006, 6(10):753-763.
[4]zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application [J]. Nat Rev Cancer, 2002, 2(5):342-350.
[5]Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges [J]. Oncologist, 2005, 10(7):528-538.
[6]Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)—16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer [J]. Clin Cancer Res, 2002, 8(12):3676-3685.
[7]Wu TC, Guarnieri FG, Staveley-O’Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens [J]. Proc Natl Acad Sci USA, 1995, 92(25):11671-11675.
[8]Auborn KJ, Wang H, Vaccariello MA, et al. Kinetics of HPV11 DNA replication after infection of keratinocytes with virions [J]. Virus Res, 1996, 43(1):85-90.
[9]Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine [J]. Cancer Gene Ther, 2006, 13(6):592-597.
[10]Chu NR, Wu HB, Wu T, et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7 [J]. Clin Exp Immunol, 2000, 121(2):216-225.
[11]Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model [J]. Cancer Res, 2000, 60(19):5456-5463.
[12]Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer [J]. J Virol, 2000, 74(6):2888-2894.
[13]Cheng WF, Hung CF, Hsu KF, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion [J]. Hum Gene Ther, 2002, 13(4):553-568.
[14]Cheng WF, Lee CN, Su YN, et al. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity [J]. Cancer Gene Ther, 2006, 13(9):873-885.
[15]Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16 [J]. J Immunol, 2001, 167(11):6471-6479.
[16]Jabbar IA, Fernando GJ, Saunders N, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins [J]. Vaccine, 2000, 18(22):2444-2453.
[17]Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides [J]. J Immunol, 1995, 154(11):5934-5943.
[18]Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive [J]. Clin Cancer Res, 2000, 6(9):3406-3416.
[19]Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model [J]. Cancer Immunol Immunother, 2006, 55(10):1267-1279.
[20]Maciag PC, Paterson Y. Technology evaluation: HspE7 (Stressgen) [J]. Curr Opin Mol Ther, 2005, 7(3):256-263.
[21]Derkay CS, Smith RJ, McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial [J]. Ann Otol Rhinol Laryngol, 2005, 114(9):730-737.
[22]Goldstone SE, Palefsky JM, Winnett MT, et al. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts [J]. Dis Colon Rectum, 2002, 45(4):502-507.
[23]Vandepapeliere P, Barrasso R, Meijer CJ, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination [J]. J Infect Dis, 2005, 192(12):2099-2107.
[24]Zhou X, Qian X, Zhao Q, et al. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model [J]. Biol Pharm Bull, 2004, 27(3):303-307.
[25]Qian X, Lu Y, Liu Q, et al. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model [J]. Immunol Lett, 2006, 102(2):191-201.
[26]Kim TW, Hung CF, Boyd D, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies [J]. J Immunol, 2003, 171(6):2970-2976.
[27]Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial [J]. Obstet Gynecol, 2004, 103(2):317-326.
[28]Zhao KJ, Cheng H, Zhu KJ, et al. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen [J]. Arch Dermatol Res, 2006, 298(2):64-72.
[29]Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus- specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer [J]. J Virol, 1999, 73(7):5402-5410.
[30]Kang TH, Lee JH, Bae HC, et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments [J]. Immunol Lett, 2006, 106(2):126-134.
[31]Hallez S, Detremmerie O, Giannouli C, et al. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity [J]. Int J Cancer, 1999, 81(3):428-437.
[32]Bubenik J, Simova J, Hajkova R, et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16 [J]. Int J Oncol, 1999, 14(3):593-597.
[33]Chang EY, Chen CH, Ji H, et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine [J]. Int J Cancer, 2000, 86(5):725-730.
[34]Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial [J]. Int J Gynecol Cancer, 2006, 16(3):1075-1081.
[35]Christensen ND, Pickel MD, Budgeon LR, et al. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas [J]. Antiviral Res, 2000, 48(2):131-142.